A Patient‐Derived Organ‐on‐Chip Platform for Modeling the Tumor Microenvironment and Drug Responses in Pancreatic Cancer
Advanced Science · 2026
DOI: 10.1002/advs.202508934 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Darbaz Adnan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Rush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Tumor Microenvironment, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Organoids. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy. Current conventional chemotherapeutics are inadequate in controlling the disease; hence, there is an urgent need for precision medicine. Ex vivo models that replicate the tumor and its microenvironment can advance precision medicine in PDAC. Patient‐derived organoids (PDOs) offer a promising solution by retaining the functional features of the tumor, allowing for individualized study of cancer biology and drug response. However, PDOs fall short in replicating the tumor microenvironment (TME), which includes various stromal and immune cells influencing tumor growth and chemoresistance. We hypothesize that combining PDO technology with organ‐on‐a‐chip (OoC) systems can enhance ex vivo cancer modeling. Here, we develop a patient‐derived platform by incorporating PDOs with key components of the TME (fibroblasts, endothelial cells, and immune cells) within a microfluidic system. This OoC model represents the crosstalk between cancer and stroma observed in PDAC in vivo. Targeting the stroma improves the effectiveness of standard chemotherapy in this OoC. Further, using this platform, we are able to model and assess the efficacy of immune checkpoint blockade for T cell cytotoxicity in PDAC. The OoC provides a pathophysiologically applicable system to support future investigations aimed at utilizing precision medicine and testing therapeutics in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, Illinois, USA.
- National Laboratory of Bioscience (LNBio), National Center of Research in Energy and Materials (CNPEM), State of Sao Paulo, Brazil.
- Gastroenterology Research Center (GRC)/Department of Internal Medicine, University of Texas Health Science Center At Houston, Houston, Texas, USA.
- Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
- Department of Pathology, Rush University Medical Center, Chicago, Illinois, USA.
- MD Anderson Cancer Center, UTHealth Houston Graduate School of Biomedical Sciences, Houston, Texas, USA.
ORCID-Profile: Darbaz Adnan, Faraz Bishehsari
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Adnan, D., de Barros, N. R., Santovito, L. S., Cheng, X., Lawrence, K. M., Barnett, M. K., Boetto, M. D., Mehta, N., Singh, A., Cheng, L., Huang, X., & Bishehsari, F. (2026). A Patient‐Derived Organ‐on‐Chip Platform for Modeling the Tumor Microenvironment and Drug Responses in Pancreatic Cancer. Advanced Science. https://doi.org/10.1002/advs.202508934
Vancouver
Adnan D, de Barros NR, Santovito LS, Cheng X, Lawrence KM, Barnett MK, et al. A Patient‐Derived Organ‐on‐Chip Platform for Modeling the Tumor Microenvironment and Drug Responses in Pancreatic Cancer. Advanced Science. 2026. doi:10.1002/advs.202508934
BibTeX
@article{Adnan2026,
author = {Adnan, Darbaz and de Barros, Natan Roberto and Santovito, Luca S and Cheng, Xuhong and Lawrence, Kristi M and Barnett, Mariah K and Boetto, Martine D and Mehta, Neal and Singh, Ajaypal and Cheng, Lin and Huang, Xiangsheng and Bishehsari, Faraz},
title = {A Patient‐Derived Organ‐on‐Chip Platform for Modeling the Tumor Microenvironment and Drug Responses in Pancreatic Cancer},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202508934}
}
EUVIMED